Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease.

Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z.

Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27642. [Epub ahead of print]

PMID:
30788890
2.

Spasmodic Dysphonia in Hereditary Spastic Paraplegia Type 7.

Hall D, Stong N, Lippa N, Pitman MJ, Pullman SL, Levy OA.

Mov Disord Clin Pract. 2018 Mar 2;5(2):221-222. doi: 10.1002/mdc3.12580. eCollection 2018 Mar-Apr. No abstract available.

3.

Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation.

Shah H, Liong C, Levy OA, Waters C, Fahn S, Marder K, Kang UJ, Wolf P, Oliva P, Zhang K, Alcalay RN, Gutierrez J.

Stroke. 2018 Aug;49(8):1977-1980. doi: 10.1161/STROKEAHA.118.021964.

PMID:
29986930
4.

Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease.

Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z.

Eur J Med Genet. 2019 Jan;62(1):65-69. doi: 10.1016/j.ejmg.2018.05.005. Epub 2018 May 26.

PMID:
29842932
5.

Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.

Sun X, Aimé P, Dai D, Ramalingam N, Crary JF, Burke RE, Greene LA, Levy OA.

Exp Neurol. 2018 May;303:95-107. doi: 10.1016/j.expneurol.2018.01.015. Epub 2018 Feb 9.

PMID:
29432724
6.

Alpha galactosidase A activity in Parkinson's disease.

Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, Ford B, Kuo SH, Vanegas N, Shah H, Liong C, Narayan S, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Oliva P, Keutzer J, Marder K, Zhang XK.

Neurobiol Dis. 2018 Apr;112:85-90. doi: 10.1016/j.nbd.2018.01.012. Epub 2018 Feb 2.

PMID:
29369793
7.

Loss of native α-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells.

Dettmer U, Ramalingam N, von Saucken VE, Kim TE, Newman AJ, Terry-Kantor E, Nuber S, Ericsson M, Fanning S, Bartels T, Lindquist S, Levy OA, Selkoe D.

Hum Mol Genet. 2017 Sep 15;26(18):3466-3481. doi: 10.1093/hmg/ddx227.

8.

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis.

Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB, Pe'er I, Di Paolo G, Alcalay RN.

PLoS One. 2017 Feb 17;12(2):e0172348. doi: 10.1371/journal.pone.0172348. eCollection 2017.

9.

SCARB2 variants and glucocerebrosidase activity in Parkinson's disease.

Alcalay RN, Levy OA, Wolf P, Oliva P, Zhang XK, Waters CH, Fahn S, Kang U, Liong C, Ford B, Mazzoni P, Kuo S, Johnson A, Xiong L, Rouleau GA, Chung W, Marder KS, Gan-Or Z.

NPJ Parkinsons Dis. 2016;2. pii: 16004. Epub 2016 Mar 10.

10.

The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease.

Robakis D, Cortes E, Clark LN, Vonsattel JP, Virmani T, Alcalay RN, Crary JF, Levy OA.

J Neural Transm (Vienna). 2016 Jun;123(6):583-8. doi: 10.1007/s00702-016-1552-3. Epub 2016 Apr 20.

11.

Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.

Aimé P, Sun X, Zareen N, Rao A, Berman Z, Volpicelli-Daley L, Bernd P, Crary JF, Levy OA, Greene LA.

J Neurosci. 2015 Jul 29;35(30):10731-49. doi: 10.1523/JNEUROSCI.0614-15.2015.

12.

Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, Mazzoni P, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Wolf P, Oliva P, Keutzer J, Marder K, Zhang X.

Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27.

13.

Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.

Romaní-Aumedes J, Canal M, Martín-Flores N, Sun X, Pérez-Fernández V, Wewering S, Fernández-Santiago R, Ezquerra M, Pont-Sunyer C, Lafuente A, Alberch J, Luebbert H, Tolosa E, Levy OA, Greene LA, Malagelada C.

Cell Death Dis. 2014 Aug 7;5:e1364. doi: 10.1038/cddis.2014.333.

14.

Knowledge of and interest in genetic results among Parkinson disease patients and caregivers.

Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN.

J Genet Couns. 2014 Feb;23(1):114-20. doi: 10.1007/s10897-013-9618-y. Epub 2013 Jun 9.

15.

The "head snap": a subtle clinical feature during the finger-nose-finger maneuver in essential tremor.

Sternberg EJ, Alcalay RN, Levy OA, Louis ED.

Tremor Other Hyperkinet Mov (N Y). 2013 Apr 18;3. pii: tre-03-159-3719-1. doi: 10.7916/D8M0444K. Print 2013.

16.

Postural and Intention Tremors: A Detailed Clinical Study of Essential Tremor vs. Parkinson's Disease.

Sternberg EJ, Alcalay RN, Levy OA, Louis ED.

Front Neurol. 2013 May 10;4:51. doi: 10.3389/fneur.2013.00051. eCollection 2013.

17.

ATF4 protects against neuronal death in cellular Parkinson's disease models by maintaining levels of parkin.

Sun X, Liu J, Crary JF, Malagelada C, Sulzer D, Greene LA, Levy OA.

J Neurosci. 2013 Feb 6;33(6):2398-407. doi: 10.1523/JNEUROSCI.2292-12.2013.

18.

Clinical reasoning: a middle-aged man with episodes of gait imbalance and a newly found genetic mutation.

Yugrakh MS, Levy OA.

Neurology. 2012 Oct 16;79(16):e135-9. doi: 10.1212/WNL.0b013e31826e9b40. No abstract available.

19.

The neuropathology of genetic Parkinson's disease.

Poulopoulos M, Levy OA, Alcalay RN.

Mov Disord. 2012 Jun;27(7):831-42. doi: 10.1002/mds.24962. Epub 2012 Mar 26. Review.

20.

Functional electrical stimulation for the treatment of lower extremity dystonia.

Barrett MJ, Bressman SB, Levy OA, Fahn S, O'Dell MW.

Parkinsonism Relat Disord. 2012 Jun;18(5):660-1. doi: 10.1016/j.parkreldis.2011.09.017. Epub 2011 Oct 5. No abstract available.

21.

Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.

Levy OA, Malagelada C, Greene LA.

Apoptosis. 2009 Apr;14(4):478-500. doi: 10.1007/s10495-008-0309-3. Review.

22.
23.

Presenilin 1 independently regulates beta-catenin stability and transcriptional activity.

Killick R, Pollard CC, Asuni AA, Mudher AK, Richardson JC, Rupniak HT, Sheppard PW, Varndell IM, Brion JP, Levey AI, Levy OA, Vestling M, Cowburn R, Lovestone S, Anderton BH.

J Biol Chem. 2001 Dec 21;276(51):48554-61. Epub 2001 Oct 17.

Supplemental Content

Support Center